Recent Press Releases

FDA Advisory Committee Finds Data Support Effectiveness of Tafamidis Meglumine, Pfizer's Novel Investigational Treatment for Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP)
Sangart Raises Additional $50M Series G Funding Following Interim Safety Analysis Of Phase 2b Study Of MP4OX In Severe Trauma Patients With Hemorrhagic Shock
Lucigen Corporation Awarded $2.8M SBIR Grant for Point of Care Diagnostics
Blueprint Medicines Welcomes Fidelity Biosciences to Investor Syndicate
Veloxis Pharmaceuticals announces a restructuring of the company to support and strengthen strategic focus on LCP-Tacro(TM) and announces changes to management
Celldex's CDX-011 Demonstrates High Response Rates in Patients with Metastatic Breast Cancer Expressing Elevated Levels of GPNMB and in Triple Negative Disease
MediciNova Reports Results of a Phase 2b Clinical Trial of MN-221 in Asthma Exacerbations
Joshua Boger Joins Alkeus Pharmaceuticals
Innovative public-private collaboration launches to tackle antibiotic research
FDA Advisory Committee Recommends Against Approval of Oral Anticoagulant XARELTO® to Reduce the Risk of Secondary Cardiovascular Events in Patients with Acute Coronary Syndrome
AVEO Initiates Phase 1 Study of AV-203, an ERBB3 Inhibitory Antibody, in Advanced Solid Tumors
Halo Therapeutics Raises $1.1 Million to Expedite Phase 2 Study of HT-100
InterMune to Divest Actimmune® (Interferon Gamma-1b)
France Biotech presents the results of its tenth annual "Life Science Panorama 2011" survey, conducted in partnership with Ernst & Young
Biopharmaceutical Companies That Attract Corporate Venture Investment More Likely to Be Acquired, Go Public, Analysis Finds
New Study Details Foreign Efforts To Lure Biopharmaceutical Companies
Alcohol intake in the elderly affects risk of cognitive decline and dementia
Lilly Diabetes Presents Phase II Blood Pressure and Heart Rate Data on Investigational GLP-1 Analog Candidate, Dulaglutide, in Patients with Type 2 Diabetes at the 27th American Society of Hypertension Scientific Meeting
Medivation and Astellas Announce Submission of New Drug Application for Enzalutamide for the Treatment of Castration-Resistant Prostate Cancer in Patients Previously Treated With Chemotherapy
Chelsea Therapeutics Completes End-of-Review Meeting With FDA for Northera (droxidopa) Capsules New Drug Application

Popular Stories

THE LIBRARY: WEBINAR

Getting the most PoC data in Phase I cancer studies

| June 12, 11am ET/ 8am PT

The hunt for proof-of-concept data is steadily moving upstream in the clinic. Join FierceBiotech on June 12th as three clinical trial experts tackle the question of how you can best design a Phase I study to get a readout on efficacy. Topics will include: enrollment, dosing and the best possible use of biomarkers for experimental cancer drugs. Register Today!

Latest Commentary

See you after Memorial Day weekend

The biggest R&D spenders in biotech

Three new rules for biopharma collaborations

The R&D revolution wants you

Download our eBook 'Supplying global clinical trials: Keys to avoiding costly delays'

EVENTS

MDMA Annual Meeting May 30th - June 1st, 2012 — Washington, DC
Clinical Trials Eastern Europe Webinar SeriesMay 15-June 12 — Eastern Europe
What's your BIO?June 18-21, 2012 — Boston, MA

Press Releases

Featured Jobs

Aseptic Operations Manager
DPT Labs - Lakewood, NJ
Sr. Director, Healthcare Compliance Audit Job
Celgene Corporation - Summit, NJ, US
Process Development Scientist - Downstream Job
Yoh - Durham, NC, USA
Program Lead - Scientific Information Architecture & Search
Merck - Kenilworth, NJ
Director, Shared Services Americas Lead Job
Celgene Corporation - Berkeley Heights, NJ, US